$MTEM
Molecular Templates, Inc.

2015 Q4 Form 10-K Financial Statement

#000156459016014457 Filed on March 10, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2015 2014 Q4
Revenue $65.87M $76.92M $3.680M
YoY Change 1689.95% 422.55% 14.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.250M $9.720M $2.620M
YoY Change -14.12% -4.14% 6.94%
% of Gross Profit
Research & Development $11.37M $40.27M $8.610M
YoY Change 32.06% 12.39% 0.94%
% of Gross Profit
Depreciation & Amortization $250.0K $300.0K $280.0K
YoY Change -10.71% -25.0% -33.33%
% of Gross Profit
Operating Expenses $13.62M $49.99M $11.23M
YoY Change 21.28% 8.73% 2.18%
Operating Profit $26.93M
YoY Change -186.17%
Interest Expense $30.00K $125.0K $20.00K
YoY Change 50.0% 3.31% -33.33%
% of Operating Profit 0.46%
Other Income/Expense, Net $17.43M $16.77M $1.560M
YoY Change 1017.31% 79.46% 578.26%
Pretax Income $69.71M $43.82M -$5.960M
YoY Change -1269.63% -301.15% -20.64%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $69.71M $43.82M -$5.964M
YoY Change -1268.9% -303.02% -21.41%
Net Earnings / Revenue 105.83% 56.97% -162.07%
Basic Earnings Per Share $0.98 $0.62 -$0.09
Diluted Earnings Per Share $0.86 $0.54 -$0.12
COMMON SHARES
Basic Shares Outstanding 70.24M
Diluted Shares Outstanding 73.48M

Balance Sheet

Concept 2015 Q4 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.70M $48.70M $58.60M
YoY Change -16.89% -16.89% -10.81%
Cash & Equivalents $4.245M $9.600M $8.391M
Short-Term Investments $39.10M $39.10M $50.20M
Other Short-Term Assets $2.600M $2.600M $800.0K
YoY Change 225.0% 225.0% -63.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $53.17M $53.20M $66.68M
YoY Change -20.26% -20.24% -22.47%
LONG-TERM ASSETS
Property, Plant & Equipment $333.0K $300.0K $557.0K
YoY Change -40.22% -50.0% -18.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $166.0K $200.0K $1.159M
YoY Change -85.68% -83.33% 9.44%
Total Long-Term Assets $499.0K $500.0K $1.716M
YoY Change -70.92% -70.59% -90.52%
TOTAL ASSETS
Total Short-Term Assets $53.17M $53.20M $66.68M
Total Long-Term Assets $499.0K $500.0K $1.716M
Total Assets $53.67M $53.70M $68.40M
YoY Change -21.53% -21.49% -34.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $725.0K $700.0K $2.074M
YoY Change -65.04% -66.67% 22.79%
Accrued Expenses $3.269M $10.10M $3.180M
YoY Change 2.8% 9.78% 0.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.83M $10.80M $25.97M
YoY Change -58.31% -58.46% -3.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.000M $2.000M $66.40M
YoY Change -96.99% -96.99% -34.0%
Total Long-Term Liabilities $2.000M $2.000M $66.40M
YoY Change -96.99% -96.99% -34.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.83M $10.80M $25.97M
Total Long-Term Liabilities $2.000M $2.000M $66.40M
Total Liabilities $12.82M $12.80M $92.37M
YoY Change -86.12% -86.15% -27.6%
SHAREHOLDERS EQUITY
Retained Earnings -$329.4M -$373.3M
YoY Change -11.74% 6.14%
Common Stock $370.3M $349.3M
YoY Change 6.01% 6.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$27.32M $40.80M -$23.98M
YoY Change
Total Liabilities & Shareholders Equity $53.67M $53.70M $68.40M
YoY Change -21.53% -21.49% -34.31%

Cashflow Statement

Concept 2015 Q4 2015 2014 Q4
OPERATING ACTIVITIES
Net Income $69.71M $43.82M -$5.964M
YoY Change -1268.9% -303.02% -21.41%
Depreciation, Depletion And Amortization $250.0K $300.0K $280.0K
YoY Change -10.71% -25.0% -33.33%
Cash From Operating Activities -$7.570M -$38.00M -$10.13M
YoY Change -25.27% 36.99% 5.41%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $109.0K -$10.00K
YoY Change -100.0% -51.34% -80.0%
Acquisitions
YoY Change
Other Investing Activities $3.420M $10.43M $6.880M
YoY Change -50.29% -55.71% -46.29%
Cash From Investing Activities $3.420M $10.32M $6.870M
YoY Change -50.22% -55.77% -46.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K 28.88M 410.0K
YoY Change -92.68% 423.19% 241.67%
NET CHANGE
Cash From Operating Activities -7.570M -38.00M -10.13M
Cash From Investing Activities 3.420M 10.32M 6.870M
Cash From Financing Activities 30.00K 28.88M 410.0K
Net Change In Cash -4.120M 1.200M -2.850M
YoY Change 44.56% 8.11% -186.89%
FREE CASH FLOW
Cash From Operating Activities -$7.570M -$38.00M -$10.13M
Capital Expenditures $0.00 $109.0K -$10.00K
Free Cash Flow -$7.570M -$38.11M -$10.12M
YoY Change -25.2% 36.28% 5.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Assets
Assets
53669000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14722000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
166000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
725000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25974000
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3961000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
712000
CY2014Q4 thld Collaboration Receivable
CollaborationReceivable
7248000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
781000
CY2015Q4 thld Collaboration Receivable
CollaborationReceivable
1891000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
333000
CY2015Q4 thld Accrued Clinical And Development Liabilities
AccruedClinicalAndDevelopmentLiabilities
6834000
CY2014Q4 thld Accrued Clinical And Development Liabilities
AccruedClinicalAndDevelopmentLiabilities
5998000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3269000
CY2015Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1864000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
125000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-21786000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-28213000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6801000
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57832000
CY2013 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
136000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16769000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60335000
CY2015 us-gaap Operating Expenses
OperatingExpenses
49987000
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
121000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57832000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
26928000
CY2014 thld Reclassification Of Fair Value Of Warrants Exercised From Liability To Equity
ReclassificationOfFairValueOfWarrantsExercisedFromLiabilityToEquity
10116000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-31251000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13453000
CY2015 thld Exercise Of Warrants To Purchase Value Of Class Common Stock
ExerciseOfWarrantsToPurchaseValueOfClassCommonStock
25000
CY2015 thld Reclassification Of Fair Value Of Warrants Exercised From Liability To Equity
ReclassificationOfFairValueOfWarrantsExercisedFromLiabilityToEquity
17000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9344000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1900000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1002000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2325000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1309000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
43822000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1506000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-13853000
CY2013 thld Exercise Of Warrants To Purchase Value Of Class Common Stock
ExerciseOfWarrantsToPurchaseValueOfClassCommonStock
1882000
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
510000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4922000
CY2013 thld Reclassification Of Fair Value Of Warrants Exercised From Liability To Equity
ReclassificationOfFairValueOfWarrantsExercisedFromLiabilityToEquity
11462000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-23475000
CY2014 thld Exercise Of Warrants To Purchase Value Of Class Common Stock
ExerciseOfWarrantsToPurchaseValueOfClassCommonStock
4834000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
686000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5488000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
6801000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
5488000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
4922000
CY2015 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
16773000
CY2014 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
9344000
CY2013 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-2325000
CY2013 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
5000
CY2015 thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-5357000
CY2014 thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-10846000
CY2013 thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
2459000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1079000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
43814000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21625000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5338000
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
80495000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2392000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2392000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3750000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11029000
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70242000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73483000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63386000
CY2013 thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
1694000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
10151000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
904000
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments which potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and marketable securities. The Company invests in a variety of financial instruments, such as, but not limited to, certificates of deposit, corporate and municipal bonds, United States Treasury and agency securities. The Company is exposed to credit risk in the event of default by the financial institutions for amounts in excess of Federal Deposit Insurance Corporation insured limits. The Company performs periodic evaluations of the relative credit standings of these financial institutions, and by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. </p></div>
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
30005000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
158000
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
101968000
CY2013 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
28000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2808000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16293000
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, revenue recognition, stock-based compensation and clinical trial accrued liabilities. </p></div>
CY2015 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-3906000
CY2015 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
1873000
CY2015 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1368000
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3051000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2865000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2308000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28100000
CY2015 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
1327547
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3460540
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
3680000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-766000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7745000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-5964000
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2015Q4 us-gaap Severance Costs1
SeveranceCosts1
2500000
CY2015Q4 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
200000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
768000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
48510000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
58577000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
39112000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
39091000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
50209000
CY2014 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
3000
CY2013 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
5000
CY2014 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2013 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2015 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014 thld Realized Gains Losses From Unrealized Gains Losses Comprehensive Income
RealizedGainsLossesFromUnrealizedGainsLossesComprehensiveIncome
0
CY2013 thld Realized Gains Losses From Unrealized Gains Losses Comprehensive Income
RealizedGainsLossesFromUnrealizedGainsLossesComprehensiveIncome
0
CY2015 thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P2M24D
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
26990000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
22000
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12100000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2949000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2616000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
593000
CY2015Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2280000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
163000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
331000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
233000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41000
CY2015Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
40
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
260000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1028000
CY2015 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
14693000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2015 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
900000
CY2014Q3 thld Aggregate Offering Price Of Common Stock
AggregateOfferingPriceOfCommonStock
30000000
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2015Q4 thld Aggregate Offering Price Of Common Stock
AggregateOfferingPriceOfCommonStock
50000000
CY2015Q4 thld Aggregate Commission Rate On Gross Proceeds For Common Stock Sold
AggregateCommissionRateOnGrossProceedsForCommonStockSold
0.030
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8300000
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8300000
CY2015Q1 thld Warrants Initial Exercise Price
WarrantsInitialExercisePrice
10.86
CY2015Q1 thld Warrant Term
WarrantTerm
P5Y
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
32558000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
11462000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
23421000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
10116000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3961000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
17000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1864000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
498411
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1250000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
7250000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1286025
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1895250
CY2014 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
179532
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4423493
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2290500
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1895250
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73282
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
179532
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8168942
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2290500
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
99759
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1327547
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9032136
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.18
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.10
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.56
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.49
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.66
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.78
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.43
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.63
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.69
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.36
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.75
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.39
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.77
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5488000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4922000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
14900000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9000000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.77
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2015 thld Share Based Compensation Arrangement By Share Based Payment Award Offering Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
P24M
CY2015 thld Employee Stock Purchase Plan Purchase Period
EmployeeStockPurchasePlanPurchasePeriod
P6M
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.85
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6801000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6500000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7407000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9592000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-448000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-571000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1794000
CY2015 thld Income Tax Reconciliation Unutilized Utilized Net Operating Losses
IncomeTaxReconciliationUnutilizedUtilizedNetOperatingLosses
-11287000
CY2014 thld Income Tax Reconciliation Unutilized Utilized Net Operating Losses
IncomeTaxReconciliationUnutilizedUtilizedNetOperatingLosses
9809000
CY2013 thld Income Tax Reconciliation Unutilized Utilized Net Operating Losses
IncomeTaxReconciliationUnutilizedUtilizedNetOperatingLosses
9747000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
898000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
730000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
486000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3135000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
952000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1416000
CY2015 thld Income Tax Reconciliation Tax Assets Not Benefited
IncomeTaxReconciliationTaxAssetsNotBenefited
4732000
CY2014 thld Income Tax Reconciliation Tax Assets Not Benefited
IncomeTaxReconciliationTaxAssetsNotBenefited
1322000
CY2013 thld Income Tax Reconciliation Tax Assets Not Benefited
IncomeTaxReconciliationTaxAssetsNotBenefited
1926000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-5703000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-3177000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
790000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
43000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
44000
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
55000
CY2015Q4 thld Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
103000
CY2014Q4 thld Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
128000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47725000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33049000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11354000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6616000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5130000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3933000
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
3681000
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-11154000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
0
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
26151000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
359000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1019000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
64671000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
70896000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
64671000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70896000
CY2015Q4 thld Net Operating Loss Deferred Tax Asset From Excess Benefits From Stock Option Exercises
NetOperatingLossDeferredTaxAssetFromExcessBenefitsFromStockOptionExercises
500000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6200000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7800000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11600000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000
CY2015 thld Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions
0
CY2015 thld Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000
CY2014 thld Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions
0
CY2014 thld Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2014 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2014Q1 us-gaap Contracts Revenue
ContractsRevenue
3681000
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
3680000
CY2014Q4 us-gaap Contracts Revenue
ContractsRevenue
3681000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7109000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12

Files In Submission

Name View Source Status
0001564590-16-014457-index-headers.html Edgar Link pending
0001564590-16-014457-index.html Edgar Link pending
0001564590-16-014457.txt Edgar Link pending
0001564590-16-014457-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201603102215225038951.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10k_20151231.htm Edgar Link pending
thld-20151231.xml Edgar Link completed
thld-20151231.xsd Edgar Link pending
thld-20151231_cal.xml Edgar Link unprocessable
thld-20151231_def.xml Edgar Link unprocessable
thld-20151231_lab.xml Edgar Link unprocessable
thld-20151231_pre.xml Edgar Link unprocessable
thld-ex121_12.htm Edgar Link pending
thld-ex231_10.htm Edgar Link pending
thld-ex311_7.htm Edgar Link pending
thld-ex312_9.htm Edgar Link pending
thld-ex321_13.htm Edgar Link pending
thld-ex322_6.htm Edgar Link pending